Journal of Surgery Concepts & Practice >

2024 , Vol. 29 >Issue 06: 549 - 554

DOI: https://doi.org/10.16139/j.1007-9610.2024.06.16

Review

Clinical application of circulating tumor cell in advanced gastric cancer

  • WANG Yizhou ,
  • WEI Qi ,
  • JIN Huimin ,
  • CHEH Lei ,
  • LIANG Haibin ,
  • ZHOU Yunlan
Expand
  • Department of General Surgery; b. Clinical Laboratory, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200082, China

Received date: 2024-01-13

  Online published: 2025-03-17

Fold

Abstract

Gastric cancer (GC) is one of the common malignant tumors globally. Its characteristics of high morbidity and mortality, high metastasis, low early diagnosis rate, low radical resection rate and low 5-year survival rate have seriously affected clinical treatment and patients’ prognosis. Circulating tumor cells (CTCs) are cancer cells that leave a solid tumor lesion and enter the bloodstream. Its diffusion and migration are important reasons for distant metastasis. In some solid tumors, enumeration of CTC has served as surrogate markers for overall survival (OS), progression-free survival (PFS) and chemotherapy effectiveness, and risk factors of relapse. Unfortunately, the study of CTC in GC is not sufficient. In this review, we collected relevant literatures and described the clinical significance of CTC for the patients with GC, especially advanced gastric cancer (AGC), including the biology, detection methods, and clinical applications of CTC, discussed the challenges and the future prospects in this field.

Key words： Circulating tumor cell (CTC); Gastric cancer (GC); Chemotherapy; Targeted therapy; Immunotherapy

Cite this article

WANG Yizhou , WEI Qi , JIN Huimin , CHEH Lei , LIANG Haibin , ZHOU Yunlan . Clinical application of circulating tumor cell in advanced gastric cancer[J]. Journal of Surgery Concepts & Practice, 2024 , 29(06) : 549 -554 . DOI: 10.16139/j.1007-9610.2024.06.16

References

[1] SUNG H, FERLAY J, SIEGEL R L, et al. Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3):209-249.
[2] AJANI J A, D’AMICO T A, BENTREM D J, et al. Gastric cancer, version 2.2022, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2022, 20(2):167-192.
[3] TAN Z. Recent advances in the surgical treatment of advanced gastric cancer:a review[J]. Med Sci Monit, 2019,25:3537-3541.
[4] CHEN M, ZHAO H. Next-generation sequencing in liquid biopsy:cancer screening and early detection[J]. Hum Genomics, 2019, 13(1):34.
[5] XU Y, ZHANG P, ZHANG K, et al. The application of CA72-4 in the diagnosis, prognosis, and treatment of gastric cancer[J]. Biochim Biophys Acta Rev Cancer, 2021, 1876(2):188634.
[6] YE Q, LING S, ZHENG S, et al. Liquid biopsy in hepatocellular carcinoma:circulating tumor cells and circulating tumor DNA[J]. Mol Cancer, 2019, 18(1):114.
[7] JU S, CHEN C, ZHANG J, et al. Detection of circulating tumor cells:opportunities and challenges[J]. Biomark Res, 2022, 10(1):58.
[8] BANYS-PALUCHOWSKI M, FEHM T, NEUBAUER H, et al. Clinical relevance of circulating tumor cells in ova-rian, fallopian tube and peritoneal cancer[J]. Arch Gynecol Obstet, 2020, 301(4):1027-1035.
[9] NERI E, DEL RE M, PAIAR F, et al. Radiomics and liquid biopsy in oncology: the holons of systems medicine[J]. Insights Imaging, 2018, 9(6):915-924.
[10] MARRUGO-RAMíREZ J, MIR M, SAMITIER J. Blood-based cancer biomarkers in liquid biopsy: a promising non-invasive alternative to tissue biopsy[J]. Int J Mol Sci, 2018, 19(10):2877.
[11] THIELE J A, BETHEL K, KRáLí?KOVá M, et al. Circulating tumor cells:fluid surrogates of solid tumors[J]. Annu Rev Pathol, 2017,12:419-447.
[12] CARLOMAGNO N, INCOLLINGO P, TAMMARO V, et al. Diagnostic, predictive, prognostic, and therapeutic molecular biomarkers in third millennium:a breakthrough in gastric cancer[J]. Biomed Res Int, 2017,2017:7869802.
[13] VASSEUR A, KIAVUE N, BIDARD F C, et al. Clinical utility of circulating tumor cells: an update[J]. Mol Oncol, 2021, 15(6):1647-1666.
[14] BAILEY P C, MARTIN S S. Insights on CTC biology and clinical impact emerging from advances in capture technology[J]. Cells, 2019, 8(6):553.
[15] ALIX-PANABIèRES C, PANTEL K. Liquid biopsy: from discovery to clinical application[J]. Cancer Discov, 2021, 11(4):858-873.
[16] SHARMA S, ZHUANG R, LONG M, et al. Circulating tumor cell isolation, culture, and downstream molecular analysis[J]. Biotechnol Adv, 2018, 36(4):1063-1078.
[17] LI Y, WU G, YANG W, et al. Prognostic value of circula-ting tumor cells detected with the CellSearch system in esophageal cancer patients: a systematic review and meta-analysis[J]. BMC Cancer, 2020, 20(1):581.
[18] NING D, CUI K, LIU M, et al. Comparison of CellSearch and circulating tumor cells (CTC)-biopsy systems in detecting peripheral blood circulating tumor cells in patients with gastric cancer[J]. Med Sci Monit, 2021,27:e926565.
[19] YANG C, ZOU K, YUAN Z, et al. Prognostic value of circulating tumor cells detected with the CellSearch System in patients with gastric cancer:evidence from a meta-analysis[J]. Onco Targets Ther, 2018,11:1013-1023.
[20] LINDGREN G, WENNERBERG J, EKBLAD L. Cell line dependent expression of EpCAM influences the detection of circulating tumor cells with CellSearch[J]. Laryngoscope Investig Otolaryngol, 2017, 2(4):194-198.
[21] RIETHDORF S, O'FLAHERTY L, HILLE C, et al. Clinical applications of the CellSearch platform in cancer patients[J]. Adv Drug Deliv Rev, 2018,125:102-121.
[22] SEXTON R E, AL HALLAK M N, DIAB M, et al. Gastric cancer:a comprehensive review of current and future treatment strategies[J]. Cancer Metastasis Rev, 2020, 39(4):1179-1203.
[23] LENGYEL C G, HUSSAIN S, TRAPANI D, et al. The emerging role of liquid biopsy in gastric cancer[J]. J Clin Med, 2021, 10(10):2108.
[24] KOLOSTOVA K, MATKOWSKI R, GüRLICH R, et al. Detection and cultivation of circulating tumor cells in gastric cancer[J]. Cytotechnology, 2016, 68(4):1095-1102.
[25] OKABE H, TSUNODA S, HOSOGI H, et al. Circulating tumor cells as an independent predictor of survival in advanced gastric cancer[J]. Ann Surg Oncol, 2015, 22(12):3954-3961.
[26] KANG H M, KIM G H, JEON H K, et al. Circulating tumor cells detected by lab-on-a-disc: role in early diagnosis of gastric cancer[J]. PLoS One, 2017, 12(6):e0180251.
[27] ZOU K, YANG S, ZHENG L, et al. Prognostic role of the circulating tumor cells detected by cytological methods in gastric cancer:a meta-analysis[J]. Biomed Res Int, 2016,2016:2765464.
[28] WANG C, YANG Z, XU E, et al. Apolipoprotein C-Ⅱ induces EMT to promote gastric cancer peritoneal metastasis via PI3K/AKT/mTOR pathway[J]. Clin Transl Med, 2021, 11(8):e522.
[29] JHI J H, KIM G H, PARK S J, et al. Circulating tumor cells and TWIST expression in patients with metastatic gastric cancer:a preliminary study[J]. J Clin Med, 2021, 10(19):4481.
[30] MANZANEDO I, PEREIRA F, SERRANO á, et al. Review of management and treatment of peritoneal metastases from gastric cancer origin[J]. J Gastrointest Oncol, 2021, 12(Suppl 1):S20-S29.
[31] ZENG C D D, JIN C C, GAO C, et al. Preoperative folate receptor-positive circulating tumor cells are associated with occult peritoneal metastasis and early recurrence in gastric cancer patients:a prospective cohort study[J]. Front Oncol, 2022,12:769203.
[32] FUGAZZOLA P, ANSALONI L, SARTELLI M, et al. Advanced gastric cancer:the value of surgery[J]. Acta Biomed, 2018, 89(8):110-116.
[33] ZHOU J, MA X, BI F, et al. Clinical significance of circulating tumor cells in gastric cancer patients[J]. Oncotarget, 2017, 8(15):25713-25720.
[34] LU R, CHEN Q, LIU X, et al. Detection of circulating stage Ⅲ-Ⅳ gastric cancer tumor cells based on isolation by size of epithelial tumor:using the circulating tumor cell biopsy technology[J]. Transl Cancer Res, 2019, 8(4):1342-1350.
[35] PERNOT S, BADOUAL C, TERME M, et al. Dynamic evaluation of circulating tumour cells in patients with advanced gastric and oesogastric junction adenocarcinoma:prognostic value and early assessment of therapeutic effects[J]. Eur J Cancer, 2017,79:15-22.
[36] ZHENG X, FAN L, ZHOU P, et al. Detection of circula-ting tumor cells and circulating tumor microemboli in gastric cancer[J]. Transl Oncol, 2017, 10(3):431-441.
[37] OKHOLM C, THORSTEINSSON M, ACHIAM M P. [Circulating tumour cells is a promising prognostic and predictive marker of gastric cancer[][J]. Ugeskr Laeger, 2014, 176(32):1490-1493.
[38] LEE S J, LEE J, KIM S T, et al. Circulating tumor cells are predictive of poor response to chemotherapy in metastatic gastric cancer[J]. Int J Biol Markers, 2015, 30(4):e382-e386.
[39] LIU Y, LING Y, QI Q, et al. Prognostic value of circula-ting tumor cells in advanced gastric cancer patients receiving chemotherapy[J]. Mol Clin Oncol, 2017, 6(2):235-242.
[40] LI Y, GONG J, ZHANG Q, et al. Dynamic monitoring of circulating tumour cells to evaluate therapeutic efficacy in advanced gastric cancer[J]. Br J Cancer, 2016, 114(2):138-145.
[41] ABBOTT M, USTOYEV Y. Cancer and the immune system:the history and background of immunotherapy[J]. Semin Oncol Nurs, 2019, 35(5):150923.
[42] WAGNER A D, SYN N L, MOEHLER M, et al. Chemotherapy for advanced gastric cancer[J]. Cochrane Database Syst Rev, 2017, 8(8):CD004064.
[43] VRANI? S, BE?LIJA S, GATALICA Z. Targeting HER2 expression in cancer:new drugs and new indications[J]. Bosn J Basic Med Sci, 2021, 21(1):1-4.
[44] ABDALLAH E A, BRAUN A C, FLORES B C T C P, et al. The potential clinical implications of circulating tumor cells and circulating tumor microemboli in gastric cancer[J]. Oncologist, 2019, 24(9):e854-e863.
[45] MISHIMA Y, MATSUSAKA S, CHIN K, et al. Detection of HER2 amplification in circulating tumor cells of HER2-negative gastric cancer patients[J]. Target Oncol, 2017, 12(3):341-351.
[46] MATSUSHITA D, UENOSONO Y, ARIGAMI T, et al. Clinical significance of circulating tumor cells in the response to trastuzumab for HER2-negative metastatic gastric cancer[J]. Cancer Chemother Pharmacol, 2021, 87(6):789-797.
[47] LI Y, ZHANG X, LIU D, et al. Evolutionary expression of HER2 conferred by chromosome aneuploidy on circula-ting gastric cancer cells contributes to developing targeted and chemotherapeutic resistance[J]. Clin Cancer Res, 2018, 24(21):5261-5671.
[48] CHéNARD-POIRIER M, SMYTH E C. Immune checkpoint inhibitors in the treatment of gastroesophageal cancer[J]. Drugs, 2019, 79(1):1-10.
[49] JIANG X, WANG J, DENG X, et al. Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape[J]. Mol Cancer, 2019, 18(1):10.
[50] TAN Z, YUE C, JI S, et al. Assessment of PD-L1 expression on circulating tumor cells for predicting clinical outcomes in patients with cancer receiving PD-1/PD-L1 blockade therapies[J]. Oncologist, 2021, 26(12):e2227-e2238.
[51] KALLERGI G, VETSIKA E K, AGGOURAKI D, et al. Evaluation of PD-L1/PD-1 on circulating tumor cells in patients with advanced non-small cell lung cancer[J]. Ther Adv Med Oncol, 2018,10:1758834017750121.
[52] WANG Y, KIM T H, FOULADDEL S, et al. PD-L1 expression in circulating tumor cells increases during radio(chemo)therapy and indicates poor prognosis in non-small cell lung cancer[J]. Sci Rep, 2019, 9(1):566.
[53] AMATATSU M, ARIGAMI T, UENOSONO Y, et al. Programmed death-ligand 1 is a promising blood marker for predicting tumor progression and prognosis in patients with gastric cancer[J]. Cancer Sci, 2018, 109(3):814-820.
[54] CHENG B, TONG G, WU X, et al. Enumeration and characterization of circulating tumor cells and its application in advanced gastric cancer[J]. Onco Targets Ther, 2019,12:7887-7896.
[55] YUE C, JIANG Y, LI P, et al. Dynamic change of PD-L1 expression on circulating tumor cells in advanced solid tumor patients undergoing PD-1 blockade therapy[J]. Oncoimmunology, 2018, 7(7):e1438111.
[56] CHEN Y, ZHOU Q, WANG H, et al. Predicting peritoneal dissemination of gastric cancer in the era of precision medicine:molecular characterization and biomarkers[J]. Cancers(Basel), 2020, 12(8):2236.
[57] NECULA L, MATEI L, DRAGU D, et al. Recent advances in gastric cancer early diagnosis[J]. World J Gastroenterol, 2019, 25(17):2029-2044.
[58] LONE S N, NISAR S, MASOODI T, et al. Liquid biopsy:a step closer to transform diagnosis, prognosis and future of cancer treatments[J]. Mol Cancer, 2022, 21(1):79.
[59] RUPP B, BALL H, WUCHU F, et al. Circulating tumor cells in precision medicine:challenges and opportunities[J]. Trends Pharmacol Sci, 2022, 43(5):378-391.
[60] LIN D, SHEN L, LUO M, et al. Circulating tumor cells: biology and clinical significance[J]. Signal Transduct Target Ther, 2021, 6(1):404.
[61] LAPIN M, TJENSVOLL K, OLTEDAL S, et al. Single-cell mRNA profiling reveals transcriptional heterogeneity among pancreatic circulating tumour cells[J]. BMC Cancer, 2017, 17(1):390.
[62] NEGISHI R, YAMAKAWA H, KOBAYASHI T, et al. Transcriptomic profiling of single circulating tumor cells provides insight into human metastatic gastric cancer[J]. Commun Biol, 2022, 5(1):20.
[63] MARKOU A, LAZARIDOU M, PARASKEVOPOULOS P, et al. Multiplex gene expression profiling of in vivo isolated circulating tumor cells in high-risk prostate cancer patients[J]. Clin Chem, 2018, 64(2):297-306.
[64] GORGES T M, KUSKE A, R?CK K, et al. Accession of tumor heterogeneity by multiplex transcriptome profiling of single circulating tumor cells[J]. Clin Chem, 2016, 62(11):1504-1515.
[65] CHEN C L, MAHALINGAM D, OSMULSKI P, et al. Single-cell analysis of circulating tumor cells identifies cumulative expression patterns of EMT-related genes in metastatic prostate cancer[J]. Prostate, 2013, 73(8):813-826.
[66] YANG C, CHEN F, WANG S, et al. Circulating tumor cells in gastrointestinal cancers:current status and future perspectives[J]. Front Oncol, 2019,9:1427.
Options
Outlines

/

〈 〉